Lumateperone and Solriamfetol interaction
Lumateperone and Solriamfetol: the Lumateperone prescribing label reports no clinically significant interaction between these two.
No clinically significant interaction reported. The label studied or considered this pair and found nothing meaningful.
What the FDA labels say
From the Lumateperone (CAPLYTA) label · effective 2025-06-20
Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples…
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.